Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2018 · 10-Q
Revenue$10.58M$10.58M−15.6% vs Q3 2017 Net Income$5.70M$5.70MN/M vs Q3 2017 EPS Diluted$0.16$0.16N/M vs Q3 2017 Gross Profit$2,345,798−8.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,283,161N/M Margins · derivedGross margin22.2%+1.7 pt vs Q3 2017
Operating margin57.7%+89.2 pt vs Q3 2017
Net margin53.9%+86.4 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end